ClinicalTrials.gg
RecruitingNCT07582432SIGMAUpdated Oct 1, 2026

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

A Phase 3 interventional study of Gamunex-C, 10% Injectable Solution in Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma, sponsored by Grifols Biologicals, LLC. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Grifols Biologicals, LLC (part of Grifols) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 1, 2026Start date movedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Planned enrollment
491st of 1,298
49 · median 36
Started
2026
with 31 others
Phase 3
114 of 1,501
17 open now
Primary completion
2028-08
later than 176 of 248 live
Registered
1,485th of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 491st largest by planned enrollment of the 1,298 interventional ones that give a count, is one of 32 that started in 2026, is one of 114 in phase 3, reaches primary completion later than 176 of the 248 other live ones, and was the 1,485th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 138 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once every 4 weeks, along with their usual medical care, for one year.

All participants will receive Gamunex-C 500 mg/kg once every 4 weeks (total 13 doses) starting Day 1 (Week 1) through Week 48 (end of Treatment Phase).

03

Conditions studied

  • Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Keywords

  • Phase 3
  • Clinical trial
  • Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants with documented and confirmed diagnosis of any of the diseases below:

  • B-cell CLL according to iwCLL criteria and Rai staging of intermediate (1 and 2) or high (3 and 4); or
  • MM according to the International Myeloma Working Group criteria (IMWG), R ISS stage II or, III; or
  • confirmed diagnosis of B-cell NHL, Stage III or above (IV, Progressive/, or recurrent/relapsed stage) according to the Lugano Classification.

Participants with HGG with IgG levels \<5g/L at screening.

Exclusion criteria

Exclusion Criteria:

  • Participants with documented history of hematopoietic stem cell transplant within 6 months before Screening Visit.
  • Participants currently receiving immunoglobulin replacement therapy (IgRT) or have received IgG replacement treatment (i.e., prior immune globulin replacement therapy) within 6 months before the Screening Visit.
  • Participants with any active infections at the time of Screening Visit. Participants with active secondary .
  • Participants with known PID.
  • Participants with a less than 1.5 years.
  • Participants with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the trial or place the participant at undue medical risk.
  • Participants who have had known serious treatment related adverse events to immunoglobulin or any anaphylactic reaction to blood or any blood-derived product.
  • Participants who have known Selective Immunoglobulin A (IgA) Deficiency (with or without antibodies to IgA) (Note: exclusion is for the specific diagnostic entity. It does not exclude other forms of humoral PI which have decreased IgA in addition to decreased IgG requiring IgG replacement).
  • Females of who are pregnant, have a positive pregnancy test at Screening Visit (serum human chorionic gonadotropin-based assay), are breastfeeding, or unwilling to practice a highly effective method of (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence*) throughout the study. Note: *True abstinence: When this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods], declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception.)
  • Participants with severe known kidney disease (as defined by estimated Chronic Kidney Disease Epidemiology Collaboration [eGFR CKD-EPI] \<30 mL/min/1.73 m2) as determined by the Principal Investigator.
  • Participants that have liver enzyme levels ( [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT], or lactate dehydrogenase [LDH]) greater than 3 times the at the Screening Visit as defined by the testing laboratory.
  • Participants who have a history (either 1 episode within the year prior to the Screening Visit or 2 previous episodes over a lifetime) of thromboembolic events [e.g., DVT, PE, ischemic stroke (, and any ischemic cerebrovascular accident), myocardial infarction (including unstable angina and ischemic heart disease diagnosed in the last 6 months), retinal artery occlusion, mesenteric ischemia, and peripheral arterial disease (Fontaine III and IV)]*.(Fontaine I: asymptomatic. IIa: mild claudication. IIb: moderate to severe claudication. III: ischemia with rest pain. IV: ulceration or gangrene).
  • Participants who currently have a known hyperviscosity syndrome or hypercoagulable states.
  • Participants who have clinical signs and symptoms consistent with current virus or virus infection.
  • Participants with non-controlled arterial hypertension (i.e., SBP > 160 mmHg and/or DBP > 100 mmHg), and/or HR >100 bpm.
  • Participants have known substance or prescription drug abuse within 12 months before the Screening Visit.
  • Participants have participated in another clinical trial within 30 days prior to Screening Visit (NOTE: observational studies without investigative treatments [non-interventional] and interventional studies to treat CLL, MM, or NHL are permitted).
  • Participants / caregivers are unwilling to comply with any aspect of the protocol for the duration of the study.
  • In the opinion of the investigator, participants may have compliance problems with the protocol and the procedures of the protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    GAMUNEX®-C administered via IV Q4W

    Drug: Gamunex-C, 10% Injectable Solution

Interventions

06

What researchers measure

Primary outcomes

  1. serious bacterial infection (SBI) rate per-participant per year.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first

Secondary outcomes

  1. Time to first onset of SBI

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first

  2. Time to first onset of severe bacterial infection

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  3. Proportion of participants who experience at least one severe bacterial infection.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  4. The rate of severe bacterial infections per participant per year.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  5. The rate of all bacterial infections per participant per year.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  6. Time to first onset of non-severe bacterial infection.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  7. The proportion of participants who experience at least one bacterial infection.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  8. The rate of infections of any kind (bacterial/viral/fungal, irrespective of severity or seriousness) per participant per year.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  9. Time to first onset of any kind of infection (bacterial/viral/fungal).

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  10. The proportion of participants who experience a validated infection

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  11. The rate of validated (as defined above) infections per participant per year

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  12. Number of days on prophylactic antibiotics (including oral, parenteral, oral plus parenteral).

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  13. The number of days on prophylactic antibiotics per participant per year

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  14. Number of days on therapeutic antibiotics (including oral, parenteral, oral plus parenteral).

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  15. The number of days on therapeutic antibiotics per participant per year

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  16. Number of hospitalizations due to any infections

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  17. Total duration of hospitalizations due to any infections

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  18. The rate of hospitalizations per participant per year due to any infections.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

  19. Rate of infections requiring IV administration of an antibiotic or antiviral/anti infective per-participant per year.

    Time frame: During treatment (1year) and up to 28 days after the last dose of study treatment or until the intake of any IgRT, other than Gamunex-C, whichever occurs first.

07

Study locations

1 of 5 sites recruiting
  • Study Site 102
    St. Petersburg, Florida 33709, United States
    Not yet recruiting
  • Study Site 101
    Fort Wayne, Indiana 46894, United States
    Recruiting
  • Study Site 105
    Westbrook, Maine 04092, United States
    Not yet recruiting
  • Study Site 104
    Columbus, Ohio 43210, United States
    Not yet recruiting
  • Study Site 103
    Tacoma, Washington 98405, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2028, 27 months after the start.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's planned 27 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → May 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
May 12, 2026
StartActual
May 11, 2026was Apr 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 23, 2026→May 11, 2026 (actual)
Oct 1, 2026
Title
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Apr 23, 2026→May 11, 2026 (now actual)
    Title A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07582432
Responsible party
Sponsor
First posted
May 12, 2026
Start date
May 11, 2026
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Judith Wessels-Kranz
Contact
judith.wesselskranz@external.grifols.com,
+49 6103 801-6395,
Marina Acosta Enslen
Contact
marina.acostaenslen@grifols.com
+1 (919) 813 9725

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion